New techniques for drug delivery to the posterior eye segment

Pharmaceutical Research

Volumn 27, Issue 4, 2010, Pages 530-543

  Eljarrat Binstock, Esther ^a   Pe'er, Jacob ^b   Domb, A J ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Drug delivery; Iontophoresis; Ocular; Posterior segment

Indexed keywords

BELLADONNA ALKALOID; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETHYLENE VINYL ACETATE COPOLYMER; EYE DROPS; EYE OINTMENT; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FLUOROURIDINE; GANCICLOVIR; HYALURONIC ACID; HYDROXYPROPYLCELLULOSE; ILUVIEN; LIPOSOME; MICROSPHERE; MIDOSTAURIN; NANOPARTICLE; NEW DRUG; PENETRATION ENHANCING AGENT; PHOTOSENSITIZING AGENT; PHOTREX; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYCAPROLACTONE; POLYMER; POLYVINYL ALCOHOL; PRODRUG; ROSTAPORFIN; SILICONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN; DRUG;

CATARACTOGENESIS; CLINICAL TRIAL; CYTOMEGALOVIRUS RETINITIS; DEVELOPED COUNTRY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; EYE DISEASE; HUMAN; INTRAOCULAR PRESSURE; IONTOPHORESIS; LONG TERM CARE; NONHUMAN; PATIENT COMPLIANCE; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL IMPAIRMENT; VITREORETINOPATHY; ANIMAL; EYE; INSTRUMENTATION; METABOLISM; METHODOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; EYE; HUMANS; IONTOPHORESIS; PHARMACEUTICAL PREPARATIONS;

EID: 77953173751     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0042-9     Document Type: Review

References (153)

1. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008;13:135-143
2. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eve: Prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006; 58: 1164-1181
3. Chastain JE. General considerations in ocular drug delivery. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker, Inc.; 2003. p. 59-107.
4. Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Advanced Drug Delivery Reviews. 2006; 58: 1258-1268
5. Ding SL. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today. 1998; 1: 328-335 (Pubitemid 28526961)
6. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Cur-rent Drug Delivery. 2006; 3: 207-217
7. K. M. Bapatla and G. Hecht. Ophthalmic ointments and suspensions. In H. A. Lieberman, R. M. Rieger, and G. S. Banker (eds.), Pharmaceutical dosage forms: disperse systems, Marcel Dekker, Inc., 2006, pp. 357-397
8. Schoenwald RD. Ocular drug delivery -pharmacokinetic considerations. Clin Pharmacokinet. 1990; 18: 225-269
9. Lee VHL, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol. 1986; 2: 67.
10. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharm Phys. 2000: 27: 558-562 (Pubitemid 30418006)
11. Ellis PP. Basic considerations. In: Ellis PP, editor. Ocular therapeutics and pharmacology. St Louis, Missouri: The C.V. Mosby Company; 1985. p. 3-27.
12. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target. 2004; 12: 623-633 (Pubitemid 40100710)
13. Robinson JR. Ocular anatomy and physiology relevant to ocular drug delivery. In: Mitra AK, editor'. Ophthalmic drug delivery systems. New York: Marcel Dekker; 1993. p. 29-57.
14. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems -Recent advances. Prog Retin Eye Res. 1998; 17: 33-58. (Pubitemid 28040752)
15. Eljarrat-Binstock E, Frucht-Pery J, Domb A. Iontophoresis for ocular drug delivery. In: Touitou E, Barry BW, editors. Enhancement in drug delivery. Boca Raton: CRC press; 2006.
16. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005; 57: 2063-2079
17. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst. 1999; 16: 85-146.
18. Raviola G. The stractural basis of the blod-ocular barriers. Exp Eye Res. 1977; 25: 27.
19. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes E, Romijn F, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. American Journal of Ophthalmology. 1999; 128: 192-197 (Pubitemid 29379772)
20. Weijtens O, Schoemaker RC, Romijn F, Cohen AF, Lentjes E, Van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002; 109: 1887-1891
21. Lee TWY, Robinson JR. Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection. J Ocul Pharm Ther. 2001; 17: 565-572
22. Kothuri MK, Pinnamaneni S, Das NG. and D. S. K. Microparticles and nanoparticles in ocular drug delivery. In: Mitra AK, editor. Ophthalmic drug delivery systems. NY: Marcel Dekker, Inc.; 2003. p. 437-466
23. Baeyens V, Percicot C, Zignani M, Deshpande AA, Kaltsatos V, Gumy R. Ocular drug delivery in veterinary medicine. Adv Drug Deliv Rev. 1997; 28: 335-361 (Pubitemid 28033907)
24. Mitra AK, Anand BS, Duvvuri S. Drug delivery to the eye. Advances in Organ Biology. 2006; 10: 307-351
25. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis - Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006: 113: 1020-1027 (Pubitemid 43795240)
26. Guidetti B, Azema J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Current Drug Delivery. 2008; 5: 7-19. (Pubitemid 351225629)
27. Bourges JL, Bloquei C, Thomas A, Froussart F, Bochot A, Azan F, et al. Intraocular implants for extended drug delivery: Therapeutic applications. Advanced Drug Delivery Reviews. 2006; 58: 1182-1202 (Pubitemid 44794429)
28. Kane FE, Burdan J, Cutino A. Green KE. Iluvien (TM): a new sustained delivery technology for posterior eye disease. Expert Opinion on Drug Delivery. 2008; 5: 1039-1046
29. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y Feasibility of drug delivery to the posterior pole of the rabbit eye with an episderal implant. Invest Ophthalmol Vis Sci. 2004; 45: 238-244 (Pubitemid 38055693)
30. Heller J. Ocular deliverv using polv(ortho esters). Advanced Drug Delivery Reviews. 2005; 57: 2053-2062
31. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology. 2007: 125: 309-317 (Pubitemid 46425557)
32. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: Potential of liposomal delivery. Progress in Retinal and Eye Research. 2000; 19: 131-147
33. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y Drug delivery systems for vitreoretinal diseases. Progress in Retinal and Eye Research. 2004; 23: 253-281 (Pubitemid 38737129)
34. Cheng LY, Hostetler KY, Chaidhawangul S, Gardner MF, Beadle JR, Keefe KS, et al. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci. 2000: 41:1523-1532 (Pubitemid 30261879)
35. Ruiz-Moreno JM, Montera JA, Arias L, Sanabria MR, Coco R, Silva R, et al. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmol Scand. 2006; 84: 743-748 (Pubitemid 44688322)
36. Woodbum KW, Engelman CJ, Blumenkranz MS. CME photodvnamic therapy for choroidal neovascularization -A review. Retin-J Retin Vitr Dis. 2002; 22: 391-405. (Pubitemid 35025513)
37. Kreuter J. Nanoparticles as bioadhesive ocular drug delivery systems. In: Lenaerts VM, Gumy R, editors. Bioadhesive Drug Delivery Systems. Boca Raton, Florida: CRC Press; 1990. p. 203-212
38. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996; 85: 530-536
39. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A, Int J Pharm. 2001; 224: 159-168 (Pubitemid 32706495)
40. Fitzgerald P, Hadgraft J, Wilson CG. A gamma sintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. J Pharm Pharmacol. 1987; 39: 487-490 (Pubitemid 17114412)
41. Gurny R, Boye T, Ibrahim H. Ocular therapy with nanoparticulate systems for controlled drug deliverv. J Control Release. 1985; 2: 353-361 (Pubitemid 16195950)
42. Diepold RW, Kreuter J, Himber J, Gurny R, Lee VHL, Robinson JR, et al. Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops as a novel depot formulation (nanoparticles). Graefe's Arch Clin Exp Ophthalmol. 1989; 227: 188-193 (Pubitemid 19066688)
43. Zimmer AK, Chetoni P, Saettone MF, Zerbe H, Kreuter J. Evaluation of Pilocarpine-Loaded Albumin Particles as Controlled Drug-Delivery Systems for the Eye. 2. Coadministration with Bioadhesive and Viscous Polymers. J Control Release. 1995; 33: 31-46.
44. Vandervoort J, Ludwig A. Preparation and evaluation of drugloaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm. 2004; 57: 251-261 (Pubitemid 38283701)
45. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: polyisobutvlcyanoacrylate, polvlactic-coglycolic acid, polv-epsiloncaprofactone. Pharm Sci. 1992; 2: 98-104.
46. Merodio M, Irache JM, Valamanesh F, Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials. 2002; 23: 1587-1594 (Pubitemid 34158581)
47. Losa C, Calvo P, Castro E, Vilajato JL, Alonso MJ. Improvement of Ocular Penetration of Amikacin Sulfate by Association to Polv(Butylcyanoacrylate) Nanoparticles. J Pharm Pharmacol. 1991: 43: 548-552
48. Alonso MJ, Losu C, Seijo B, Torres D, Vila-Jato JL. Ner ophthalmic drug release systems: formulation and ocular disposition of amikacin loaded nanoparticles. 5th Int Conf Pharm Tech. 1989: 1: 77-83.
49. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002: 16: 53-61. (Pubitemid 34756782)
50. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol. 1996; 48: 1147-1152 (Pubitemid 126449485)
51. Bucolo C, Maltese A, Maugeri F, Busa B, Puglisi G, Pignatello R. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J Pharm Pharmacol. 2004; 56: 841-846 (Pubitemid 38885976)
52. Calvo P, Sanchez A, Martinez J, Lopez MI, Calonge M, Pastor JC, et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res. 1996; 13: 311-315 (Pubitemid 26074197)
53. Le Bourlais C, Chevanne F, Turlin B, Acar L, Zia H, Sado PA, et al. Effect of cyclosporin A formulations on bovine corneal absorption: ex-vivo study. J microencapsul. 1997; 14: 457-467 (Pubitemid 27313368)
54. De Kozak Y, Andrieux K, Villarroya H, Klein C, ThillayeGoldenberg B, Naud MC, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol. 2004; 34: 3702-3712 (Pubitemid 40012188)
55. Bejjani R, Benezra D, Cohen H, Rieger J, Andrieu C, Jeanny JC, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis. 2005; 11: 124-132 (Pubitemid 41358300)
56. Bejjani RA, Behar-Cohen F, Benezra D, Gurny R, Delie F. Polymeric nanoparticles for drug delivery to the posterior segment of the eye. Chimia. 2005; 59: 344-347 (Pubitemid 40935281)
57. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et ai Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003: 44: 3562-3569
58. Eljarrat-Binstock E, Domb AJ. Nanoparticles in ocular drug delivery. In: Domb AJ, Tabata Y, Ravi Kumar' MNV, Farber S, editors. Nanoparticles for pharmaceutical applications. California: American Scientific Publishers; 2007. p. 367-376
59. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol. 2007: 18: 235-239 (Pubitemid 46624923)
60. Moritera T, Ogura Y, Yoshimura N, Honda Y, Wada R, Hyon SH, et al. Biodegradable Microspheres Containing Adriamycin in the Treatment of Proliferative Vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992; 33: 3125-3130
61. Peyman GA, Conway M, Khoobehi B, Soike K. Clearance of Microsphere-Entrapped 5-Fluorouracil and Cytosine-Arabinoside from the Vitreous of Primates. Int Ophthalmol. 1992; 16:109-113
62. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of Biodegradable Polymers as a Drug-Delivery System in the Vitreous. Invest Ophthalmol Vis Sci. 1991; 32: 1785-1790
63. Saishin Y, Silva RL, Saishin Y, Callahan K, Schoch C, Ahlheim M, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci. 2003; 44: 4989-4993 (Pubitemid 37315317)
64. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the anti-VEGF aptamer EYEOOl with poly(lactic-co- glycolic) acid microspheres. Invest Ophthalmol Vis Sci. 2003; 44: 290-299
65. Conway BR. Recent patents on ocular drug delivery systems. Recent Patents on Drug Delivery & Formulation. 2008; 2: 1-8. (Pubitemid 351546429)
66. G. P. Cook, L. Burgess, J. Wing, T. Dowie, P. Calias, D. T. Shima, C. K., D. Allison, S. Volker, and P. Schmidt. Preparation and characterization of pegaptanib sustained release microsphere formulations for intraocular application, Invest Ophthalmol Vis Sei. 47: E-Abstract 5123 (2006).
67. Mainardes RM, Urban MCC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, el al. Colloidal carriers for ophthalmic drug delivery. Curr- Drug Targets. 2005; 6: 363-371
68. Fattal E, Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Advanced Drug Delivery Reviews. 2006; 58: 1203-1223
69. Dos Santos ALG, Bochet A, Fattal E. Intraocular delivery of oligonucleotides. Current Pharmaceutical Biotechnology. 2005; 6: 7-15.
70. Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Research. 2008; 48: 319-324 (Pubitemid 351179511)
71. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, Urth A. Gold nanoparticles enable selective light-induced contents release from liposomes. Journal of Controlled Release. 2007;122:86-93. (Pubitemid 47284557)
72. Irache JM, Merodio M, Arnedo A, Camapanero MA, Mirshahi M, Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini-Reviews in Medicinal Chemistry. 2005; 5: 293-305. (Pubitemid 40331045)
73. Bochot A, Fattal E, Boutet V, Deverre JR, Jeanny JC, Chacun H, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci. 2002; 43: 253-259 (Pubitemid 34032467)
74. L. Pitkanen, J. Pelkonen, M. Ruponen, S. Ronkko, and A. Urtti. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model, Aaps Journal. 6:(2004).
75. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharmaceutical Research. 2003; 20: 576-583 (Pubitemid 36438900)
76. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Reviews Drug Discovery. 2006; 5: 123-132
77. Eljarrat-Binstock E, Domb AJ. Iontophoresis: A non-invasive ocular drug delivery. J Control Release. 2006; 110: 479-489 (Pubitemid 43163439)
78. Kasting GB. Theoretical models for iontophoretic delivery. Adv Drug Deliv Rev. 1992: 9: 177-199
79. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev. 2001; 46: 281-305.
80. Molokhia S, Jeong EK, Higuchi W, Li K. Examination of barriers and barrier alteration in transscleral iontophoresis. Journal of Pharmaceutical Sciences. 2008; 97: 831-844 (Pubitemid 351293884)
81. Bridger MW. Keene M, Graham JM, Healey R, Ammar MM. A device for iontophoretic anesthesia of the tympanic membrane. J Med Eng Technol. 1982; 6: 62-64 (Pubitemid 12533737)
82. Zempsky WT, Sullivan J, Paulson DM, Hoath SB. Evaluation of a low-dose lidocaine iontophoresis system for topical anesthesia in adults and children: A randomized, controlled trial. Clin Ther. 2004; 26: 1110-1119 (Pubitemid 39141814)
83. Moppett IK, Szypula K, Yeoman PM. Comparison of EMLA and lidocaine iontophoresis for cannulation analgesia. Eur J Anaesthesiol. 2004; 21: 210-213 (Pubitemid 38297918)
84. Decou JM, Abrams RS, Hammond JH, Lowder LR, Gauderer MWL. Iontophoresis: a needle-free, electrical system of local anesthesia delivery for pediatric surgical office procedures. J Pediatr Surg. 1999; 34: 946-949
85. Carter EP, Barrett AD, Heeley AF, Kuzemko JA. Improved sweat test method for the diagnosis of cvstic fibrosis. Arch Dis Child. 1984; 59: 919-922
86. Gangarosa LP, Hill JM, Thompson BL, Leggett C, Rissing JP. Iontophoresis of vidarabine monophosphate for herpes orolabialis. J Infect Dis. 1986; 154: 930-934
87. Krauser JT. Hypersensitive teeth. Part II: Treatment. J Prosthet Dent. 1986; 56: 307-311
88. Rigano W, Yanik M, Barone FA, Baibak G, Cislo C. Antibiotic iontophoresis in the management of burned ears. J Burn Care Rehabilitation. 1992; 13: 407-409
89. Wirtz R. Die ionentherapie in der augenheilkunde. Klin Monatsbl Augenheilkd. 1908; 46: 543-579
90. Myles ME, Loutsch JM, Higaki S, Hill JM. Ocular iontophoresis. In: Mitra AK, editor. Ophthalmic drug delivery svstems. New York: Marcel Dekker, Inc.; 2003. p. 365-408.
91. Barza M, Peckman C, Baum J. Transscleral Iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology. 1986; 93: 133-139 (Pubitemid 16132699)
92. Frucht-Pery J, Goren D, Solomon A, Siganos CS, Mechoulam H, Solomon A, et al. The distribution of gentamicin in the rabbit cornea following iontophoresis to the central cornea. J Ocul Pharmacol Ther. 1999; 15: 251-256 (Pubitemid 29262982)
93. Rootman DS, Hobden JA, Jantzen JA, Gonzalez JR, Ocallaghan RJ, Hill JM. Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit. Arch Ophthalmol. 1988; 106: 262-265
94. Yoshizumi MO, Cohen D, Verbukh I, Leinwand M, Kim J, Lee DA. Experimental transscleral iontophoresis of ciprofloxacin. J Ocular Pharmacol. 1991; 7: 163-167
95. Eljarrat-Binstock E, Raiskup F, Stepensky D, Domb AJ, FruchtPery J. Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest Ophthalmol Vis Sci. 2004; 45: 2543-2548 (Pubitemid 38998848)
96. Hill JM, Park NH, Gangarosa LP, Hull DS, Tuggle CL, Bowman K, et al. Iontophoresis of vidarabine monophosphate into rabbit eyes. Invest Ophthlmol Vis Sci. 1978; 17: 473-476
97. Lam TT, Fu J, Chu R, Stojack K, Siew E, Tso MOM. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis. J Ocul Pharmacol. 1994; 10: 571-575 (Pubitemid 24321156)
98. Grossman R, Lee DA. Transscleral and transcorneal iontophoresis of ketoconazole in the rabbit eye. Ophthalmology. 1989; 96: 724-729
99. Behar-Cohen FF, El Aouni A, Gautier S, David G, Davis J, Chapon P, et al. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: Influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res. 2002; 74: 51-59
100. Behar-Cohen FF, Parel JM, Pouliquen Y, Thillaye-Goldenberg B, Goureau O, Heydolph S, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res. 1997; 65: 533-545 (Pubitemid 27454953)
101. Lam TT, Edward DP, Zhu XA, Tso MOM. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol. 1989; 107: 1368-1371
102. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release. 2005; 106: 386-390
103. Eljarrat-Binstock E, Orucov F, Frucht-Peiy J, Pe'er J, Domb AJ. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. J Ocul Pharm Ther. 2008; 24: 344-350
104. Hayden BC, Jockovich ME, Murray TG, Voigt M, Milne P, Kralinger M, et al. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004; 45: 3644-3649
105. Kondo M, Araie M. Iontophoresis of 5-fluorouracil into the conjunctiva and sclera. Invest Ophthalmol Vis Sci. 1989: 30: 583-585
106. Eljarrat-Binstock E, Domb AJ, Orucov F, Frucht-Pery J, Pe'er J. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res. 2007; 32: 639-646
107. Eljarrat-Binstock E, Domb AJ, Orucov F, Frucht-Pery J, Pe'er J. In vitro and in vivo evaluation of carboplatin delivery to the eye using hydrogel-iontophoresis. Curr Eye Res. 2008; 33: 269-275
108. Asahara T, Shinomiya K, Naito T, Shiota H. Induction of gene into the rabbit eye by iontophoresis: Preliminary report. Jpn J Ophthalmol. 2001; 45: 31-39
109. Berdugo M. Valamanesh F, Andrieu C, Klein C, Benezra D, Courtois Y, et al. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev. 2003: 13: 107-114
110. Andrieu-Soler C, Doat M, Halhal M, Keller N, Jonet L, Benezra D, et al. Enhanced oligonucleotide delivery to mouse retinal cells using iontophoresis. Mol Vis. 2006: 12: 1098-1107
111. Voigt M, De Kozak Y, Halhal M, Courtois Y, Behar-Cohen F. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem Biophys Res Commun. 2002; 295: 336-341
112. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm. 2001; 215: 57-65.
113. Kishida A, Ikada Y Hydrogels for biomedical and pharmaceutical applications. In: Dumitriu S, editor. Polvmeric biomaterials. Inc, New York: Marcel Dekker; 2002. p. 133-145
114. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000; 50: 27-46.
115. Banga AK, Chien YW. Hydrogel-based iontotherapeutic delivery devices for transdermal deliverv of peptide/protein drugs. Pharm Res. 1993; 10: 697-702.
116. Fang JY, Hsu LR, Huang YB, Tsai YH. Evaluation of transdermal iontophoresis of enoxacin from polymer formulations: in vilro skin permeation and in vivo microdialysis using Wistar rat as an animal model. Int J Pharm. 1999; 180: 137-149
117. Fang JY, Sung KC, Wang JJ, Chu CC, Chen KT. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hvdrogels. J Pharm Pharmacol. 2002; 54: 1329-1337
118. Eljarrat-Binstock E, Bentolila A, Kumar N, Harel H, Domb A. Preparation, characterization and sterilization of hydrogel sponges for iontophoretic drug- delivery use. Polym Adv Tech. 2007; 18: 720-730
119. Fischer GA, Parkinson TM, Szlek MA. OcuPhor - The future of ocular drug delivery. Drug Delivery Tech. 2002; 2: 50-52
120. Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther. 2003; 19: 145-151
121. Parkinson TM, Miller DJ, Lloyd LB, Hamilton S, Brown S, Koss A, et al. The effects of in vivo iontophoresis on rabbit eye structure and retinal function. Invest Ophthalmol Vis Sci. 2000; 41: S772.
122. Vollmer DL, Szlek MA, Kolb K, Lloyd LB, Parkinson TM. In vivo transscleral iontophoresis of amikacin to rabbit eyes. J Ocul Pharmacol Ther. 2002: 18: 549-558
123. Hastings MS, Li SK. Miller DJ, Bernstein PS, Mufson D. Visulex: advancing iontophoresis for effective noninvasive backto-the-eye therapeutics. Drug Delivery Tech. 2004; 4: 53-57
124. Eljarrat-Binstock E, Orucov F, Aldouby Y, Frucht-Pery J, Domb AJ. Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J Control Release. 2008; 126: 156-161
125. Frucht-Pery J, Mechoulam H, Siganos CS, Ever-Hadani P, Shapiro M, Domb A. Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel deliverv probe. Exp Eve Res. 2004; 78: 745-749
126. J. W. Higuchi, W. I. Higuchi, S. K. Li, S. A. Molokhia, D. J. Miller, R. P. Kochambilli, K. Papangkorn, D. C. Mix, and A. L. Tuitupou. Noninvasive delivery of a transscleral sustained release depot of triamcinolone acetonide using the Visulex device to treat posterior uveitis, Invest Ophthalmol Vis Sci. 48: E-Abstract 5822 (2007).
127. W. Higuchi, A. L. Tuitupou, R. P. Kochambilli, D. C. Mix, G. Yan, J. W. Higuchi, and S. K. Li. Delivery of sustained release formulation of triamcinolone acetonide to the rabbit eye using the Visulex ocular' iontophoresis device, Invest Ophthalmol Vis Sei. 47:E-Abstract 5108 (2006).
128. K. Papangkorn, W. I. Higuchi, S. K. Li, R. P. Kochambilli, A. L. Tuitupou, D. C. Mix, and J. W. Higuchi. Delivery of an Immunosuppressive Agent into the Rabbit Eye Using the Visulex®Ocular Iontophoresis Device, Invest Ophthalmol Vis Sci. 48:E-Abstract 5818 (2007).
129. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. Hydrogel probe for iontophoresis drug delivery to the eye. J Biomater Sci Polym Ed. 2004; 15: 397-413.
130. Grossman R, Chu DF, Lee DA. Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis. Invest Ophthalmol Vis Sci. 1990; 31: 909-916
131. Choi TB, Lee DA. Transscleral and Transcorneal Iontophoresis of Vancomycin in Rabbit Eyes. J Ocul Pharmacol. 1988; 4: 153-164
132. Rootman DS, Jantzen JA, Gonzalez JR, Fischer MJ, Beuerman R, Hill JM. Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Invest Ophthalmol Vis Sci. 1988: 29: 1397-1401
133. Hobden JA, Ocallaghan RJ, Hill JM, Reidy JJ, Rootman DS, Thompson HW. Tobramycin Iontophoresis into Corneas Infected with Drug-Resistant Pseudomonas-Aeruginosa. Curr Eye Res. 1989; 8: 1163-1169
134. Hobden JA, Reidy JJ, Ocallaghan RJ, Insler MS, Hill JM. Ciprofloxacin Iontophoresis for Aminoglycoside-Resistant Pseudomonal Keratitis. Invest Ophthalmol Vis Sci. 1990; 31: 1940-1944
135. Barza M, Peckman C, Baum J. Transscleral Iontophoresis as an Adjunctive Treatment for Experimental Endophthalmitis. Arch Ophthalmol. 1987; 105: 1418-1420
136. Chapon P, Voigt M, Gautier S, Behar-Cohen F, O'grady G, Parel JM. Intraocular tissues pharmacokinetics of ganciclovir transscleral Coulomb controlled iontophoresis in rabbits. Invest Ophthalmol Vis Sci. 1999; 40: S189-9.
137. Kralinger MT, Voigt M, Kieselbach GF, Hamasaki D, Hayden BC, Parel JM. Ocular delivery of acetylsalicylic acid by repetitive Coulomb-controlled iontophoresis. Ophthalmic Res. 2003: 35: 102-110
138. Sarraf D, Equi RA, Holland GN, Yoshizumi MO, Lee DA. Transscleral Iontophoresis of Foscarnet. Am J Ophthalmol. 1993: 115: 748-754
139. Voigt M, Kralinger M, Kieselbach G, Chapon P, Anagnoste S, Hayden B, et al. Ocular aspirin distribution: A comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci. 2002; 43: 3299-3306
140. Souied EH, Reid SNM, Piri NI, Lerner LE, Nusinowitz S, Farber DB. Non-invasive gene transfer by iontophoresis for therapv of an inherited retinal degeneration. Experimental Eye Research. 2008: 87: 168-175
141. Erlanger G. Iontophoresis, a scientific and practical tool in ophthalmology. Ophthalmologica. 1954; 128: 232-246
142. Hughes L, Maurice DM. A fresh look at iontophoresis. Arch Ophthalmol. 1984; 102: 1825-1829
143. Barza M, Peckman C, Baum J. Transscleral Iontophoresis of Gentamicin in Monkeys. Invest Ophthalmol Vis Sci. 1987; 28: 1033-1036
144. Lam TT, Fu J, Tso MOM. A Histopathologic Study of Retinal Lesions Inflicted by Transscleral Iontophoresis. Graefes Arch Clin Exp Ophthalmol. 1991; 229: 389-394
145. Yoshizumi MO, Lee DA, Sarraf DA, Equi RA, Verdon W. Ocular Toxicity of Iontophoretic Foscamet in Rabbits. J Ocul Pharmacol Ther. 1995; 11: 183-189
146. Chauvaud D, Behar-Cohen FF, Parel JM, Renard G. Transscleral Iontophoresis of cortcicosteoids: Phase II clinical trial. Invest Ophthalmol Vis Sci. 2000: 41: S79-9.
147. Halhal M, Renard G, Bejjani RA, Behar-Cohen F. Corneal graft rejection and corticoid iontophoresis: 3 case reports. J Fr Ophtalmol. 2003; 26: 391-395
148. Behar-Cohen FF, Halhal M, Benezra D, Chauvaud D, Renard G. Reversal of corneal graft rejection by iontophoresis of methylprednisolone. Invest Ophthalmol Vis Sci. 2002;43: U504-4.
149. Halhal M, Renard G, Courtois Y, Benezra D, Behar-Cohen F. Iontophoresis: from the lab to the bed side. Exp Eye Res. 2004; 78: 751-757
150. Burstein NL, Leopold IH, Bemacchi DB. Trans-scleral iontophoresis of gentamicin. J Ocul Pharmacol. 1985; 1: 363-368
151. Yoshizumi MO, Roca JA, Lee DA, Lee G, Gomez I. Ocular Iontophoretic supplementation of intravenous foscamet therapy. Am J Ophthalmol. 1996; 122: 86-90.
152. A. L. Tuitupou, W. I. Higuchi, S. K. Li, D. J. Miller, R. P. Kochambilli, J. W. Higuchi, K. Papangkom, and D. C. Mix. Enhanced transscleral delivery of dexamethasone phosphate with a vasoconstrictor in the treatment of uveitis in a rabbit model, Invest Ophthalmol Vis Sci. 48:E-Abstract 5821 (2007).
153. Horwath-Winter J, Schmut O, Haller-Schober EM, Gruber A, Rieger G. Iodide iontophoresis as a treatment for dry eye syndrome. Br J Ophthalmol. 2005; 89: 40-44 (Pubitemid 40040236)